Given the ongoing implementation of sensitive mutation detection methodologies, such as next-generation sequencing (NGS), and the increased use of circulating cell-free DNA NGS techniques, physicians are increasingly likely to encounter cases of EGFR mutation-positive NSCLC with uncommon mutations in everyday practice, for which the clinical evidence base is narrow.23-25 Therefore, more clinical data are required to inform treatment decisions in such cases. Here, EGFR is linked to non-small cell lung carcinoma.